1) Radionuclide therapy
Targeted alpha therapy using actinium for pancreatic cancer treatment (Ac-FAPI-04)
In collaboration with Heidelberg University, we have successfully developed new alpha-therapy targeting FAP (Fibroblast Activation Protein), which is expressed in the stroma of many cancer types. 1)
When a single dose of this drug ([Ac-225] FAPI-04) was administered intravenously to a mouse model of pancreatic cancer, it selectively accumulated in tumors, showing an inhibitory effect on tumor growth. 1)
It has been confirmed for the first time in the world that a therapeutic effect can be obtained by attacking the cancer stroma, which supports the growth of cancer cells, with alpha rays.
The overall survival rate of cancer patients is increasing, but the 5-year relative survival rate for pancreatic cancer is still fairly low at 10%, and the effectiveness of current treatments is limited.
We will optimize this drug and aim to be an effective treatment for patients with refractory pancreatic cancer in the future.
1) Watabe T, et al. J Nucl Med. 2019